Simple Protein Redesign Produces the Most Active Designed Enzyme Ever

Key Takeaways

• X‑ray fragment screening identified 43 weak binders to ABLE protein.
• Combined with just two rounds of directed evolution, KABLE achieved 10× activity.
• Simple helical ABLE became both an enzyme and a fluorescent sensor.
• Record‑breaking designed enzyme KABLE outperforms previous catalysts by tenfold.
• Method could speed custom enzyme development for pharma and manufacturing.

Pulse Analysis

The fusion of crystallographic fragment screening with directed evolution marks a paradigm shift in de novo protein engineering. By soaking a designed helical bundle (ABLE) with hundreds of small‑molecule fragments and mapping their binding sites at synchrotron facilities, the team generated a high‑resolution interaction map that would be impossible to obtain through computational docking alone. This structural insight allowed researchers to pinpoint weak, promiscuous binding events and rapidly channel them into functional redesigns, cutting the typical evolutionary cycle from many rounds to just two.

Beyond the methodological novelty, the results underscore the untapped potential of minimalist protein scaffolds. ABLE’s simple helix, traditionally viewed as too rudimentary for catalysis, was transformed into KABLE—a Kemp eliminase that outperforms all prior designed enzymes by a factor of ten. The achievement was amplified by AI‑assisted modeling that guided mutation choices, illustrating how machine learning can accelerate the leap from weak binders to high‑efficiency catalysts. This demonstrates that catalytic power does not strictly require complex folds, opening avenues for designing compact, stable enzymes suited for harsh industrial conditions.

The broader implications span pharmaceuticals, green chemistry, and synthetic biology. Rapidly generated, highly active enzymes could streamline the synthesis of complex drug intermediates, reducing reliance on toxic metal catalysts and lowering production costs. In manufacturing, bespoke biocatalysts like KABLE promise greener pathways for polymer and fine‑chemical synthesis. As the technique matures, we can expect a surge in custom enzyme platforms that accelerate innovation across the life‑science and chemical sectors.